Multiple inhibitors are developed to target the SET domain of EZH2 to inhibit the catalytic activity, including EPZ-6438 (tazemetostat),688 CPI-1205,689 GSK126,690 C24,691 and UNC1999.692 Tazemetostat, a first-in-class oral EZH2 inhibitor, was approved by FDA in 2020 for the treatment of relapsed follicular lymphoma (Table 1). This evidence concerns the gene EZH2 and follicular lymphoma.